Search Results 361-370 of 16423 for HMB loading phase

  1. A Study to Evaluate ALZT-OP1a in Subjects with Mild-to-Moderate Amyotrophic Lateral Sclerosis - Mayo Clinic

    Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

  2. A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) - Mayo Clinic

    Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

  3. Sorafenib for Hepatopulmonary Syndrome - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  4. Neurology - Clinical trials

    This randomized phase III trial compares memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing ...

  5. A Study to Evaluate the Safety and Effectiveness of DCR-PHXC to Treat Patients with Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment - Mayo Clinic

    Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

  6. Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer - Mayo Clinic

    Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

  7. A Study Of Epilepsy, Changes In Hormones, And Ovarian Function During Menopause (ECHO) - Mayo Clinic

    Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

  8. Synergy with Grid Therapy and Immune Checkpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

    The primary objective of this study is to describe the safety and toxicity of grid + immunotherapy in stage IV NSCLC using CTCAE v5.0. Participation eligibility.

  9. Abiraterone/Prednisone, Olaparib, Or Abiraterone/Prednisone + Olaparib In Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects - Mayo Clinic

    This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate cancer (mCRPC).

  10. Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion - Mayo Clinic

    Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...